Clearside Biomedical (CLSD) Competitors

Clearside Biomedical (NASDAQ:CLSD) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Do analysts recommend CLSD or TERN?

Clearside Biomedical currently has a consensus price target of $5.25, suggesting a potential upside of 503.66%. Terns Pharmaceuticals has a consensus price target of $18.38, suggesting a potential upside of 425.00%. Given Clearside Biomedical's stronger consensus rating and higher probable upside, equities analysts plainly believe Clearside Biomedical is more favorable than Terns Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearside Biomedical	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Terns Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Is CLSD or TERN more profitable?

Terns Pharmaceuticals has a net margin of 0.00% compared to Clearside Biomedical's net margin of -413.83%. Clearside Biomedical's return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clearside Biomedical	-413.83%	N/A	-92.90%
Terns Pharmaceuticals	N/A	-32.76%	-31.33%

Does the MarketBeat Community favor CLSD or TERN?

Clearside Biomedical received 331 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 67.39% of users gave Clearside Biomedical an outperform vote while only 59.72% of users gave Terns Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Clearside Biomedical	Outperform Votes 374 67.39%	Underperform Votes 181 32.61%
Terns Pharmaceuticals	Outperform Votes 43 59.72%	Underperform Votes 29 40.28%

Which has higher valuation & earnings, CLSD or TERN?

Clearside Biomedical has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearside Biomedical	$1.66M	40.39	-$32.49M	-$0.47	-1.85
Terns Pharmaceuticals	N/A	N/A	-$90.21M	-$1.13	-3.10

Do institutionals & insiders have more ownership in CLSD or TERN?

18.8% of Clearside Biomedical shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 9.2% of Clearside Biomedical shares are held by insiders. Comparatively, 15.1% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, CLSD or TERN?

Clearside Biomedical has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500.

Does the media favor CLSD or TERN?

In the previous week, Terns Pharmaceuticals had 4 more articles in the media than Clearside Biomedical. MarketBeat recorded 7 mentions for Terns Pharmaceuticals and 3 mentions for Clearside Biomedical. Terns Pharmaceuticals' average media sentiment score of 1.48 beat Clearside Biomedical's score of 0.29 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clearside Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Terns Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Clearside Biomedical beats Terns Pharmaceuticals on 11 of the 17 factors compared between the two stocks.